Free Trial

20 Stocks Wall Street Analysts Love the Most - 13 of 20

 
 

Novo Nordisk A/S (NYSE:NVO)

Consensus Rating
Moderate Buy
Rating Score
2.8
Ratings Breakdown
6 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$145.25 (85.9% Upside)

About Novo Nordisk A/S

Novo Nordisk A/S logoNovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. More about Novo Nordisk A/S
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
3/3/2025Stifel NicolausDowngradeBuy ➝ Hold
2/12/2025Morgan StanleyInitiated CoverageEqual Weight
1/8/2025UBS GroupUpgradeSell ➝ Buy
1/6/2025Sanford C. BernsteinUpgradeUnderperform ➝ Market Perform
12/23/2024BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$156.00 ➝ $105.00
12/2/2024BNP ParibasUpgradeStrong-Buy
11/6/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
10/17/2024BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$160.00 ➝ $156.00
10/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00